Novo Nordisk和Septerna合作伙伴在2.2B项目中开发治疗肥胖和糖尿病的口服药物。 Novo Nordisk and Septerna partner on $2.2B project to develop oral drugs for obesity and diabetes.

丹麦制药公司Novo Nordisk与美国生物技术公司Septerna合作开发治疗肥胖,2型糖尿病和其他心脏代谢疾病的口服药物. Danish pharmaceutical Novo Nordisk and US biotech Septerna have partnered to develop oral drugs for obesity, type 2 diabetes, and other cardiometabolic diseases. 这一合作价值约22亿美元,包括四个针对特定受体的初步发展方案。 The collaboration, worth about $2.2 billion, includes four initial development programs targeting specific receptors. 塞佩纳将利用其专有平台开发这些治疗方法,诺沃·诺迪斯克将承担所有研发成本。 Septerna will use its proprietary platform to develop these treatments, with Novo Nordisk covering all R&D costs.